Search Results - "Ma, Anna W"

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers by Sun, Kaiming, Atoyan, Ruzanna, Borek, Mylissa A, Dellarocca, Steven, Samson, Maria Elena S, Ma, Anna W, Xu, Guang-Xin, Patterson, Troy, Tuck, David P, Viner, Jaye L, Fattaey, Ali, Wang, Jing

“…Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and…”
Get full text

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma by Galloway, Thomas J, Wirth, Lori J, Colevas, Alexander D, Gilbert, Jill, Bauman, Julie E, Saba, Nabil F, Raben, David, Mehra, Ranee, Ma, Anna W, Atoyan, Ruzanna, Wang, Jing, Burtness, Barbara, Jimeno, Antonio

“…CUDC-101 is a small molecule that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone…”
Get full text

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion by Wang, Jing, Pursell, Natalie W, Samson, Maria Elena S, Atoyan, Ruzanna, Ma, Anna W, Selmi, Abdelkader, Xu, Wanlu, Cai, Xiong, Voi, Maurizio, Savagner, Pierre, Lai, Cheng-Jung

“…CUDC-101 is a novel, small-molecule, anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2. It is currently in phase I clinical…”
Get full text

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma by Younes, Anas, Batlevi, Connie Lee, Cohen, Jonathon B., de Vos, Sven, Landsburg, Daniel J., Myint, Zaw Win, Patel, Krish, Phillips, Tycel J., Smith, Sonali M., Westin, Jason R., Ma, Anna W, Grayson, Dena, von Roemeling, Reinhard, Barta, Stefan K.

“…Background High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double- and triple-hit lymphoma), as well as diffuse large B-cell…”
Get full text

Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma by Landsburg, Daniel Jeffrey, Kelly, Kevin, Viner, Jaye, Wang, Jing, Gong, Lucy, Clancy, Myles Steven, Ma, Anna W, Oki, Yasuhiro

“…Abstract only…”
Get full text

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma by Booher, Robert N, Nowakowski, Grzegorz S., Patel, Krish, Lunning, Matthew A., Samson, Maria Elena S., Atoyan, Ruzanna, Ma, Anna W, Xu, Guang-Xin, Dellarocca, Steven, Modafferi, Holly, Borek, Mylissa, Zhang, Zhidong, Parker, Jefferson, Whitney, Duncan, Wang, Hongwei, Tuck, David P, Younes, Anas

“…Background: IRAK4 kinase activity is required for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid…”
Get full text

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas by Lee, James J., Powderly, John D., Patel, Manish R., Brody, Joshua, Hamilton, Erika Paige, Infante, Jeffrey R., Falchook, Gerald Steven, Wang, HongWei, Adams, Lisa, Gong, Lucy, Ma, Anna W, Wyant, Timothy, Lazorchak, Adam, Agarwal, Shefali, Tuck, David P., Daud, Adil

“…Abstract only TPS3099 Background: Programmed-death 1 (PD-1) and V-domain Ig suppressor of T-cell activation (VISTA) are independent immune checkpoints that…”
Get full text

Abstract 5502: IAP inhibitor CUDC-427 induces tumor regression or stasis in preclinical models of B cell lymphoma by Tian, Ze, Sun, Kaiming, Patterson, Troy, Atoyan, Ruzanna, Borek, Mylissa, Samson, Maria, Hantzis, Brianne, Ma, Anna W., Dellarocca, Steven, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Evasion from apoptosis is a characteristic of human cancers. The family of Inhibitor of Apoptosis (IAP) proteins plays a pivotal role in apoptosis,…”
Get full text

Abstract 4634: Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies by Sun, Kaiming, Atoyan, Ruzanna, Borek, Mylissa A., Dellarocca, Steven, Samson, Maria E., Ma, Anna W., Xu, Guangxin, Patterson, Troy, Tuck, David P., Viner, Jaye L., Fattaey, Ali, Wang, Jing

“…Abstract MYC family genes are among the most frequently deregulated oncogenic drivers in human cancer. Pharmacologic inhibition of HDAC activity and blockade…”
Get full text

Abstract 917: Post-treatment changes in levels of TNF family ligands and XIAP may predict sensitivity to IAP antagonist CUDC-427 by Atoyan, Ruzanna, Samson, Maria Elena S., Hantzis, Brianne, Ma, Anna W., Yin, Ling, Borek, Mylissa, Dellarocca, Steven, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Inhibitors of apoptosis (IAP) proteins are a novel target for cancer therapy. Antagonists of IAP proteins have been shown to synergize with TNF…”
Get full text

Abstract 4324: Predictive biomarker signatures for IAP inhibitor CUDC-427 by Sun, Kaiming, Tian, Ze, Zhang, Qi, Samson, Maria, Atoyan, Ruzanna, Borek, Mylissa, Dellarocca, Steven, Zifcak, Brian, Patterson, Troy, Ma, Anna W., Xu, Guangxin, Wick, Michael J., Rickles, Richard, Wang, Jing

“…Abstract The Inhibitors of Apoptosis (IAP) are a family of functionally related proteins that serve as endogenous regulators of apoptosis. The frequent…”
Get full text

A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma by Galloway, Thomas, Wirth, Lori J., Colevas, Alexander D., Gilbert, Jill, Bauman, Julie E., Saba, Nabil F., Raben, David, Mehra, Ranee, Ma, Anna W., Atoyan, Ruzanna, Wang, Jing, Burtness, Barbara, Jimeno, Antonio

Get full text

Abstract 1879: Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies by Ma, Anna W., Atoyan, Ruzanna, Younes, Anas, Flinn, Ian W., Oki, Yasuhiro, Copeland, Amanda, Berdeja, Jesus G., Laliberte, Robert, Viner, Jaye, Samson, Maria Elena S., Dellarocca, Steven, Yi, Ling, Borek, Mylissa, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K)/AKT pathway are promising therapeutic targets in hematologic cancers and…”
Get full text

Employment Transitions, Child Care Conflict, and the Mental Health of Low-Income Urban Women With Children by Jacobs, Anna W., MS, MA, Hill, Terrence D., PhD, Tope, Daniel, PhD, O'Brien, Laureen K., MA

“…Abstract Objective Although studies suggest that employment promotes mental health, it is unclear whether this pattern extends to low-income urban women with…”
Get full text